American Oncology Network Reports Strong Growth and Record Milestones in 2025
American Oncology Network (AONC) reported exceptional growth for the 12 months ended June 30, 2025, with annual revenue exceeding $2 billion, representing over 40% growth year-over-year. The network has expanded to include more than 300 oncology and hematology providers across 20 states.
Key achievements include the launch of bispecific T-cell engager therapies in 40+ clinics, expansion of radioligand therapies, and implementation of AI-enabled clinical trial matching. The company demonstrated strong value-based care performance, achieving $6 million in CMS cost savings and $2.7 million in commercial savings. Partner practices average a 30% increase in sustainable income after joining AON.
American Oncology Network (AONC) ha registrato una crescita eccezionale nei 12 mesi chiusi il 30 giugno 2025, con ricavi annuali superiori a $2 miliardi, pari a oltre un 40% di crescita su base annua. La rete si è ampliata fino a comprendere oltre 300 medici e specialisti in oncologia e ematologia in 20 stati.
Tra i risultati principali figurano l'introduzione di terapie bispecifiche attivanti le cellule T in oltre 40 cliniche, l'espansione delle terapie radioligandiche e l'implementazione di un sistema di matching per studi clinici potenziato dall'IA. L'azienda ha dimostrato solide performance nella cura basata sul valore, ottenendo $6 milioni di risparmi nei costi CMS e $2,7 milioni di risparmi commerciali. Le strutture partner registrano in media un incremento del 30% del reddito sostenibile dopo l'affiliazione ad AON.
American Oncology Network (AONC) registró un crecimiento excepcional en los 12 meses cerrados el 30 de junio de 2025, con ingresos anuales superiores a $2.000 millones, lo que representa más del 40% de crecimiento interanual. La red se ha ampliado para incluir a más de 300 especialistas en oncología y hematología en 20 estados.
Logros clave: lanzamiento de terapias bispecíficas que activan células T en más de 40 clínicas, expansión de terapias radioligadas e implementación de emparejamiento de ensayos clínicos potenciado por IA. La compañía mostró un sólido desempeño en atención basada en el valor, logrando $6 millones en ahorros de costos CMS y $2,7 millones en ahorros comerciales. Las prácticas asociadas experimentan, en promedio, un aumento del 30% en ingresos sostenibles después de unirse a AON.
American Oncology Network (AONC)는 2025년 6월 30일로 종료된 12개월 동안 연매출 $20억를 넘기며 전년 대비 40% 이상 성장하는 탁월한 성과를 기록했습니다. 네트워크는 20개 주에 걸쳐 300명 이상의 종양학·혈액학 의료진으로 확장되었습니다.
주요 성과로는 40개 이상의 클리닉에서 이중특이적 T세포 유도(바이소페식) 치료 도입, 방사성리간드 치료 확대, 인공지능 기반 임상시험 매칭 시스템 도입 등이 있습니다. 회사는 가치 기반 의료 부문에서도 강한 성과를 보이며 CMS 비용 절감 $6백만과 상업적 절감 $2.7백만을 달성했습니다. 파트너 기관은 AON에 합류한 후 평균적으로 지속 가능한 수익이 30% 증가했습니다.
American Oncology Network (AONC) a affiché une croissance exceptionnelle pour les 12 mois clos le 30 juin 2025, avec un chiffre d'affaires annuel supérieur à $2 milliards, soit une croissance de plus de 40% d'une année sur l'autre. Le réseau s'est étendu pour regrouper plus de 300 praticiens en oncologie et hématologie dans 20 États.
Parmi les réalisations clés figurent le déploiement de thérapies bispécifiques activant les lymphocytes T dans plus de 40 cliniques, l'expansion des thérapies par radioligands et la mise en place d'un système d'appariement des essais cliniques assisté par IA. L'entreprise a démontré de solides performances en matière de soins axés sur la valeur, générant $6 millions d'économies CMS et $2,7 millions d'économies commerciales. Les cabinets partenaires enregistrent en moyenne une augmentation de 30% des revenus durables après leur adhésion à AON.
American Oncology Network (AONC) verzeichnete für die 12 Monate bis zum 30. Juni 2025 ein herausragendes Wachstum: der Jahresumsatz überstieg $2 Milliarden, was einem Zuwachs von über 40% gegenüber dem Vorjahr entspricht. Das Netzwerk wurde auf mehr als 300 onkologische und hämatologische Leistungserbringer in 20 Bundesstaaten ausgeweitet.
Zu den wichtigsten Erfolgen zählen die Einführung von bispezifischen T‑Zell‑Engager‑Therapien in über 40 Kliniken, der Ausbau von Radioligandentherapien und die Implementierung einer KI‑gestützten Zuordnung für klinische Studien. Das Unternehmen erzielte starke Ergebnisse in der wertorientierten Versorgung und realisierte $6 Millionen an CMS‑Kosteneinsparungen sowie $2,7 Millionen an kommerziellen Einsparungen. Partnerpraxen verzeichnen im Durchschnitt eine 30%ige Steigerung des nachhaltigen Einkommens nach dem Beitritt zu AON.
- Revenue surpassed $2 billion with >40% year-over-year growth
- Network expanded to over 300 providers across 20 states
- Partner practices average >30% increase in sustainable income after joining
- Achieved $8.7 million in combined cost savings through value-based care initiatives
- Successfully launched advanced immunotherapy treatments in 40+ clinics
- Implemented AI-enabled clinical trial matching technology
- 39% improvement in social risk factors contributing to improved health outcomes
- Financial results have not been audited or reviewed by independent accountants
- Significant expansion may pose integration and management challenges
Insights
AON demonstrates exceptional growth with 40%+ revenue increase to $2B, network expansion to 300+ providers, and strong value-based care performance.
American Oncology Network (AON) has delivered remarkable financial performance, with annual revenue surpassing
The network's growth metrics are particularly impressive, now encompassing more than 300 oncology and hematology providers across 20 states – a substantial footprint expansion that strengthens their competitive positioning in community oncology. Their partner recruitment model appears highly effective, with practices averaging a
What truly differentiates AON's growth story is their multi-faceted value creation. Beyond pure network expansion, they've delivered
Their investments in innovative technologies (AI-enabled trial matching, cloud-based laboratory systems) and expanded treatment options (BiTE therapies, radioligand treatments) position them well for continued growth. The executive leadership expansion further signals their preparation for sustained scaling, with strategic additions in legal, human resources, and growth operations.
What stands out is AON's ability to maintain this growth trajectory while demonstrating measurable value-based care outcomes, including a
Annual revenue surpasses
FORT MYERS, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- American Oncology Network (AON), one of the fastest-growing networks of community-based oncology practices in the United States, today announced the achievement of multiple key milestones. Fueled by new and expanding partnerships, groundbreaking treatment innovations, and a steadfast commitment to patient-centered care, AON continues to advance its mission of delivering world-class oncology care to more communities across the country.
With annual revenue surpassing
Looking ahead, AON is inviting new partners to join its growing national network, where they can preserve clinical autonomy and focus on patients while growing revenue with access to best-in-class support infrastructure including an in-house specialty pharmacy, revenue cycle management, prior authorization, innovative data and technology, and more. AON partner practices average a greater than
“AON’s growth and momentum reflects the strength of our model and the commitment of our partner practices to transform how cancer care is delivered in communities across the country,” said Todd Schonherz, chief executive officer of AON. “We’re not just growing—we’re delivering measurable improvements in patient access, experience and outcomes.”
2025 YTD Growth and Innovation Highlights
- Nationwide Expansion
The network added dozens of new practices and providers, growing to more than 300 oncology and hematology specialists across 20 states. Recent partnerships include Fort Wayne Medical Oncology and Hematology, MidAmerica Cancer Care, Auerbach Hematology and Oncology, and Conway Hematology Oncology.
Further, several AON partner practices added new clinic locations, expanded existing ones, and recruited new physicians across the country. Growth will continue through the remainder of 2025, as AON is currently recruiting providers for 16 clinic locations across the country and will welcome four additional new physicians next month.
- Launch of Groundbreaking Immunotherapies
More than 40 AON-affiliated clinics began offering bispecific T-cell engager (BiTE) therapies, expanding access to advanced immunotherapy in community settings.
- Radiology and Radioligand Therapy Expansion
AON broadened access to cutting-edge radioligand therapies (RLT), offering targeted treatments for certain metastatic and rare cancers.
- Increased Lab Efficiency Through Cloud-Based Systems
AON launched a cloud-based laboratory information system to streamline the integration of complex pathology reports, improving efficiency across its pathology and oncology labs.
- Clinical Trial Innovation with AI-Empowered Data Technology for Patient Matching
To enhance access to clinical trials, AON co-created MiBA, a leader in AI-enabled trial matching and patient navigation. The collaboration supports faster, more precise identification and recruitment for oncology clinical trials. - Value-Based Care Leadership
AON had several advancements in value-based care:- Achieved nearly
$6 million in cost savings for CMS from the CMS Enhancing Oncology Model (EOM) and partnered with a large multi-state commercial value-based care organization, which led to$2.7 million in cumulative savings. - Launched self-funded employer contracting consisting of 1 million covered lives, aligned with value-based benefit design principles.
- Implemented a social risk navigation platform, leading to a
39% improvement in social risk factors contributing to improved health outcomes.
- Achieved nearly
- National Recognition and Research Impact
AON physicians and executives participated in 14 sessions at the 2025 Community Oncology Alliance (COA) Annual Meeting and presented 24 research studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Fifteen additional studies will be presented at ASCO’s Quality of Care Symposium in October 2025.
- CAP Laboratory Reaccreditation
AON’s central laboratory in Fort Myers, Florida, earned reaccreditation from the College of American Pathologists (CAP), following a rigorous on-site inspection.
- Executive Leadership Expansion
To support continued growth, AON appointed several senior leaders in the first half of 2025, including Charlie Goddard as general counsel, Terri Casey as chief human resources officer, and Joe Verschleiser as chief growth and performance officer.
A Vision for the Remainder of 2025
AON is positioned to amplify its national impact by advancing clinical innovation, strengthening partnerships and supporting the long-term sustainability of community oncology. Practices that join AON gain access to a robust suite of services and tools that help them grow while delivering exceptional care.
“We remain committed to ensuring that every patient receives personalized, high-quality care while reducing costs and improving outcomes,” said Dr. Stephen “Fred” Divers, chief medical officer of AON. “We’re proud to welcome new providers who share our vision and dedication to advancing care in the communities where patients live.”
For more information about AON, visit AONcology.com.
Financial Disclosure Advisory
This press release contains certain financial results for the twelve month period ended June 30, 2025. The financial results have not been audited or reviewed by the Company’s independent registered public accounting firm. Accordingly, the Company’s independent registered public accounting firm does not express an opinion with respect thereto, and you should not place undue reliance on such financial results. This press release also contains forward-looking statements, including but not limited to statements regarding anticipated growth, future treatment offerings, physician recruitment, and potential financial outcomes. These statements are based on current expectations and projections and are subject to risks and uncertainties that may cause actual results to differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. AON assumes no obligation to update or revise any such statements unless required by law.
About American Oncology Network
American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 300 providers practicing across 20 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. For more information, please visit AONcology.com or follow us on LinkedIn, Facebook, X (formerly Twitter) and YouTube.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/81dce631-359c-4260-bd21-ef215507f62d
Media Contact: Karen Riley Sawyer American Oncology Network Karen.Sawyer@AONcology.com
FAQ
What was American Oncology Network's (AONC) revenue growth in 2025?
How many healthcare providers are in the American Oncology Network as of 2025?
What cost savings did AONC achieve through value-based care in 2025?
How much do partner practices increase their income after joining American Oncology Network?
What new treatment innovations did American Oncology Network introduce in 2025?
